Apr 25, 2022 11:17 AM ISTGlenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement.
Apr 14, 2022 04:52 PM IST Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher.
Apr 11, 2022 10:46 AM IST Glenmark will initiate Phase 1 clinical trial in India by June 2022 for its small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor
Mar 21, 2022 10:18 AM IST The approval granted by the US Food & Drug Administration (USFDA) to the company's arm Glenmark Pharmaceuticals Inc, USA, is for Lacosamide tablets of strengths 50 mg, 100 mg, 150 mg and 200 mg, Glenmark said in a statement.
Feb 22, 2022 07:20 AM IST RRG (Relative Rotation Graphs) analysis indicates expected outperformance from banks, metals and auto sectors and expected underperformance from realty, media and IT. Gold has registered fresh breakout on charts and likely to perform well.
Feb 15, 2022 06:36 PM IST ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 550 in its research report dated February 14, 2022.
Jan 28, 2022 12:12 PM IST The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC’s MetroGel-Vaginal, the drug firm said in a statement.
Jan 14, 2022 10:15 AM IST The company’s fully-owned unit Glenmark Specialty SA (Switzerland) has received approval from the USFDA for its new drug application (NDA) for Ryaltris, a fixed-dose (metered), prescription, combination nasal spray, Glenmark Pharmaceuticals said in a statement.
Jan 13, 2022 03:21 PM IST Net Sales are expected to increase by 10.3 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs 3,073.1 crore, according to Prabhudas Lilladher.
Nov 18, 2021 03:02 PM IST Geojit recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 575 in its research report dated November 18, 2021.
Nov 16, 2021 02:58 PM IST Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 600 in its research report dated November 16, 2021.
Nov 16, 2021 10:46 AM IST Glenmark Pharmaceuticals has been listed on the Dow Jones Sustainability Index under the category of emerging markets for the fourth consecutive year, the company has said
Oct 06, 2021 06:00 PM IST Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.4 percent Q-o-Q) to Rs 2,786.7 crore, according to Prabhudas Lilladher.
Aug 19, 2021 01:02 PM IST ICICI Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 680 in its research report dated August 16, 2021.
Jul 27, 2021 09:47 AM IST In order to address the opportunities in oncology, peptides and iron compounds, Glenmark Life Science plans to build an R&D pipeline in the coming years
Jul 27, 2021 09:26 AM IST Glenmark Life Sciences IPO: The company has debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible.
Jul 20, 2021 02:04 PM IST The move is being seen as a value-unlocking exercise in a niche segment which is fetching attractive valuations and will provide investors the option of betting on a pure play API business. Glenmark Pharma’s stock has risen by 15 per cent in the last 3 months.
Jun 04, 2021 02:28 PM IST Geojit is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 717 in its research report dated June 03, 2021.
Jun 01, 2021 04:14 PM IST Prabhudas Lilladher recommended reduce rating on Glenmark Pharmaceuticals with a target price of Rs 509 in its research report dated Jun 01, 2021.
Jun 01, 2021 09:37 AM IST Here is what brokerages have to say about the stock and the company after the March quarter earnings
May 29, 2021 01:46 PM IST The company had posted a net profit of Rs 220.30 crore in the corresponding period of the previous fiscal, Glenmark said in a late regulatory filing on Friday.
Apr 17, 2021 12:27 PM IST Two years ago, Glenmark Pharmaceuticals had attempted to sell a minority stake in its API business to private equity funds but those plans did not fructify. Post the Q3FY21 results, the management indicated that API growth outlook remained strong for the next two-three years owing to a favourable demand-supply scenario.
Mar 24, 2021 01:47 PM IST "The company has received approval from the United States Food and Drug Administration (USFDA) for Chlorpromazine Hydrochloride tablets USP, in the strengths of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg," Glenmark said in a regulatory filing.
Mar 23, 2021 02:42 PM IST The loan to Glenmark will help it increase the availability of affordable, quality medicines in the country as well in other countries, including treatment for the pandemic.
Mar 23, 2021 02:33 PM IST The company has received final approval from the United States Food & Drug Administration (USFDA) for Diltiazem Hydrochloride extended-release capsules USP, in the strengths of 60 mg, 90 mg, and 120 mg, Glenmark said in a statement.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
